GLYC Logo

GlycoMimetics, Inc. (GLYC) 

NASDAQ
Market Cap
$19.47M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
311 of 966
Rank in Industry
185 of 554

Largest Insider Buys in Sector

GLYC Stock Price History Chart

GLYC Stock Performance

About GlycoMimetics, Inc.

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Insider Activity of GlycoMimetics, Inc.

Over the last 12 months, insiders at GlycoMimetics, Inc. have bought $83,159 and sold $488,749 worth of GlycoMimetics, Inc. stock.

On average, over the past 5 years, insiders at GlycoMimetics, Inc. have bought $2.2M and sold $3.43M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Rock Edwin (Chief Medical Officer) — $78,825. Hahn Brian M. (SVP Finance, CFO) — $4,335.

The last purchase of 115,000 shares for transaction amount of $30,717 was made by Rock Edwin (Chief Medical Officer) on 2024‑06‑21.

List of Insider Buy and Sell Transactions, GlycoMimetics, Inc.

2024-08-08Sale10 percent owner
260,873
0.4135%
$0.19$50,009-7.68%
2024-08-07Sale10 percent owner
61,488
0.0996%
$0.18$11,197+0.09%
2024-08-06Sale10 percent owner
55,732
0.0882%
$0.18$10,188-2.68%
2024-08-05Sale10 percent owner
164,523
0.2612%
$0.19$30,996-4.86%
2024-08-02Sale10 percent owner
286,200
0.4383%
$0.20$57,354-13.35%
2024-08-01Sale10 percent owner
63,564
0.0987%
$0.22$13,743-18.47%
2024-07-30Sale10 percent owner
756,835
1.1897%
$0.22$167,185-1.31%
2024-07-29Sale10 percent owner
363,949
0.5697%
$0.24$85,637-24.40%
2024-07-26Sale10 percent owner
258,335
0.4016%
$0.24$62,440-26.31%
2024-06-21PurchaseChief Medical Officer
115,000
0.1787%
$0.27$30,717-28.10%
2024-06-20PurchaseChief Medical Officer
190,000
0.2799%
$0.25$48,108-26.00%
2024-06-18PurchaseSVP Finance, CFO
17,500
0.0252%
$0.25$4,335-23.55%
2023-09-22PurchaseChief Medical Officer
30,403
0.0463%
$1.38$41,956+6.38%
2023-09-21PurchaseChief Medical Officer
35,000
0.0544%
$1.38$48,300+8.70%
2023-05-17SaleSVP Finance, CFO
3,700
0.0059%
$1.95$7,215-15.69%
2023-05-10Purchasedirector
30,000
0.0441%
$1.56$46,800-1.14%
2023-05-08PurchaseSVP & Chief Commercial Officer
13,500
0.0237%
$1.57$21,195+18.24%
2023-02-24Purchase10 percent owner
100,000
0.1667%
$1.70$170,000-5.33%
2023-02-23Purchase10 percent owner
200,000
0.3399%
$1.75$350,760-6.14%
2023-02-22Purchase10 percent owner
150,000
0.2504%
$1.79$268,995-9.83%

Insider Historical Profitability

2.59%
Invus Public Equities, L.P.10 percent owner
6317565
9.7971%
$0.3089<0.0001%
Rock EdwinChief Medical Officer
680403
1.0552%
$0.3070<0.0001%
Hahn Brian M.SVP Finance, CFO
70643
0.1096%
$0.3023+32.26%
BVF PARTNERS L P/IL10 percent owner
4980812
7.7241%
$0.3030<0.0001%
BARRIS PETER J10 percent owner
4702791
7.293%
$0.3012<0.0001%
NEW ENTERPRISE ASSOCIATES 10 L P10 percent owner
4702791
7.293%
$0.3012<0.0001%
BARRETT M JAMES
4702791
7.293%
$0.3012<0.0001%
NEW ENTERPRISE ASSOCIATES 13 LP10 percent owner
4093377
6.3479%
$0.3010<0.0001%
SANDELL SCOTT Ddirector
2237196
3.4694%
$0.3018<0.0001%
HENOS MICHAEL Adirector
469454
0.728%
$0.3024+27.18%
Magnani John L.SVP of Research, CSO
366078
0.5677%
$0.3014+32.26%
King Rachel K.President, CEO
356064
0.5522%
$0.3001
Thackray Helen M.SVP Clinical Development, CMO
148615
0.2305%
$0.3009
Johnson Bruce SSVP & Chief Commercial Officer
138980
0.2155%
$0.3010+18.24%
JUNIUS DANIEL Mdirector
93250
0.1446%
$0.3050+18.64%
Andrews Patricia Sdirector
45250
0.0702%
$0.3010<0.0001%
Girard ArmandSVP, Chief Business Officer
29161
0.0452%
$0.3011+32.26%
Semerjian HaroutChief Executive Officer
25000
0.0388%
$0.3010+32.26%
PEARSON TIMOTHY Rdirector
24650
0.0382%
$0.3010+32.26%
Goldberg Mark Alandirector
11497
0.0178%
$0.3010+23.55%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Bvf Inc Il$28.63M14.819.54M0%+$00.21
Artal Group S A$25.77M13.328.59M0%+$00.11
Nea Management Company Llc$11.51M5.953.84M-19.51%-$2.79M0.05
Octagon Capital Advisors LP$9M4.653M0%+$00.05
The Vanguard Group$8.29M4.292.76M+14.04%+$1.02M<0.0001
AXA$4.76M2.461.59M+0.03%+$1,329.000.01
Goldman Sachs$3.34M1.731.11M+21.25%+$586,059.00<0.01
Millennium Management LLC$2.24M1.16746,954+1,820.78%+$2.12M<0.01
BlackRock$2.2M1.14732,567-0.33%-$7,248.00<0.0001
Susquehanna International Group$1.66M0.86554,594+397.43%+$1.33M<0.01
Geode Capital Management$1.52M0.78505,147+5.48%+$78,811.60<0.0001
Acadian Asset Management$991,000.000.51330,526-38.92%-$631,581.63<0.01
Jane Street Capital$867,825.000.45289,275+406.23%+$696,396.00<0.01
Qube Research & Technologies$661,044.000.34220,348+4,440.45%+$646,485.00<0.01
Marshall Wace$652,503.000.34217,501+1,588.02%+$613,848.00<0.01
Connor Clark & Lunn Investment Management Ltd$542,361.000.28180,787+26.11%+$112,284.00<0.01
State Street$537,795.000.28179,265-4.02%-$22,500.00<0.0001
Bridgeway Capital Management$505,800.000.26168,600-14.5%-$85,800.000.01
Verition Fund Management Llc$487,284.000.25162,428New+$487,284.000.01
Hrt Financial Llc$467,000.000.24155,830New+$467,000.00<0.01
Man Group Plc$449,577.000.23149,859New+$449,577.00<0.01
Renaissance Technologies$425,000.000.22141,700+13.87%+$51,755.82<0.01
Citigroup$413,001.000.21137,667+539.48%+$348,417.00<0.0001
Northern Trust$386,271.000.2128,757+15.73%+$52,509.00<0.0001
Sargent Investment Group Llc$324,000.000.17108,000+86.21%+$150,000.000.08
Morgan Stanley$309,264.000.16103,088+198.71%+$205,731.00<0.0001
Adage Capital Partners Gp L L C$300,000.000.16100,0000%+$0<0.01
Simplex Trading Llc$271,000.000.1490,652+25.13%+$54,428.990.01
JPMorgan Chase$253,872.000.1384,624+5,146.37%+$249,033.00<0.0001
American Century Investments$190,926.000.163,642New+$190,926.00<0.0001
LINSCO PRIVATE LEDGER CORP$174,000.000.0958,000+41.46%+$51,000.00<0.0001
Point72 Asia Singapore Pte Ltd$155,604.000.0851,868New+$155,604.000.02
Intellectus Partners$152,160.000.0850,7200%+$00.04
Bank of America$152,829.000.0850,943+154.84%+$92,859.00<0.0001
Cubist Systematic Strategies$149,394.000.0849,798New+$149,394.00<0.01
Letko Brosseau$135,750.000.0745,2500%+$0<0.01
Y Intercept Hong Kong Ltd$129,390.000.0743,130+62.31%+$49,674.000.01
Balyasny Asset Management Llc$121,671.000.0640,557New+$121,671.00<0.0001
IEQ Capital$115,089.000.0638,3630%+$0<0.01
Jefferies Financial Group$114,600.000.0638,200New+$114,600.00<0.01
ExodusPoint Capital Management, LP$107,000.000.0635,698-62.72%-$180,024.85<0.01
OMERS$91,800.000.0530,600New+$91,800.00<0.01
Two Sigma Advisers LP$87,900.000.0529,300-82.28%-$408,300.00<0.0001
Group One Trading$86,037.000.0428,679-8.24%-$7,722.00<0.01
Tower Research Capital$70,866.000.0423,622+719.64%+$62,220.00<0.01
Brevan Howard Capital Management Lp$70,017.000.0423,339New+$70,017.000.01
Dimensional Fund Advisors$69,468.000.0423,156New+$69,468.00<0.0001
Charles Schwab$67,083.000.0422,3610%+$0<0.0001
Belvedere Trading LLC$61,395.000.0320,465New+$61,395.00<0.01
Squarepoint Ops LLC$60,945.000.0320,315New+$60,945.00<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.